Medical Supply Company have recently partnered with MDNA Life Sciences who are pioneers in the field of mitochondrial biology and genomics, using ground-breaking discoveries to develop a range of innovative molecular tests for hard to diagnose diseases.
As a result of this partnership MSC, together with MDNA Life Sciences is delighted to bring the Mitomic Prostate Test (MPT™) to the market for clinical use in Ireland.
This CE-IVD market MPT™ assay is a qualitative real-time polymerase chain reaction assay for detection of the 3.4kb mitochondrial DNA deletion in human plasma, from men whose PSA results leave them in the Grey Zone.
The MPT™ is the most accurate way of determining if a patient is at risk of having clinically significant prostate cancer from a simple blood test. Its high negative predictive value (97-100%) enables a more accurate and informed biopsy decisions independent of PSA result or age. Therefore, reducing the number of unnecessary biopsies by up to 30%.
MDNA Life Sciences’ company mission is to put an end to unnecessary surgical procedures with their extensive range of tests that can significantly improve diagnosis, treatment, prognosis and monitoring.
For more information on the MPT click here